Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
2001 1
2002 4
2003 9
2004 7
2005 6
2006 3
2007 4
2008 6
2009 4
2010 8
2011 5
2012 13
2013 25
2014 19
2015 32
2016 29
2017 18
2018 21
2019 39
2020 36
2021 27
2022 30
2023 28
2024 32
2025 42
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

404 results

Results by year

Filters applied: . Clear all
Page 1
Refining colorectal cancer classification and clinical stratification through a single-cell atlas.
Khaliq AM, Erdogan C, Kurt Z, Turgut SS, Grunvald MW, Rand T, Khare S, Borgia JA, Hayden DM, Pappas SG, Govekar HR, Kam AE, Reiser J, Turaga K, Radovich M, Zang Y, Qiu Y, Liu Y, Fishel ML, Turk A, Gupta V, Al-Sabti R, Subramanian J, Kuzel TM, Sadanandam A, Waldron L, Hussain A, Saleem M, El-Rayes B, Salahudeen AA, Masood A. Khaliq AM, et al. Genome Biol. 2022 May 11;23(1):113. doi: 10.1186/s13059-022-02677-z. Genome Biol. 2022. PMID: 35538548 Free PMC article.
Epigenetics in hepatocellular carcinoma.
Nagaraju GP, Dariya B, Kasa P, Peela S, El-Rayes BF. Nagaraju GP, et al. Semin Cancer Biol. 2022 Nov;86(Pt 3):622-632. doi: 10.1016/j.semcancer.2021.07.017. Epub 2021 Jul 26. Semin Cancer Biol. 2022. PMID: 34324953 Review.
Appendiceal Mucinous Neoplasms: Diagnosis and Management.
Shaib WL, Assi R, Shamseddine A, Alese OB, Staley C 3rd, Memis B, Adsay V, Bekaii-Saab T, El-Rayes BF. Shaib WL, et al. Oncologist. 2017 Sep;22(9):1107-1116. doi: 10.1634/theoncologist.2017-0081. Epub 2017 Jun 29. Oncologist. 2017. PMID: 28663356 Free PMC article. Review.
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Yau T, et al. JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12. JAMA Oncol. 2020. PMID: 33001135 Free PMC article. Clinical Trial.
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. Suker M, et al. Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Lancet Oncol. 2016. PMID: 27160474 Free PMC article.
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
Melero I, Yau T, Kang YK, Kim TY, Santoro A, Sangro B, Kudo M, Hou MM, Matilla A, Tovoli F, Knox J, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Soleymani S, Yao J, Neely J, Tschaika M, Hsu C, El-Khoueiry AB. Melero I, et al. Ann Oncol. 2024 Jun;35(6):537-548. doi: 10.1016/j.annonc.2024.03.005. Epub 2024 May 22. Ann Oncol. 2024. PMID: 38844309 Free article. Clinical Trial.
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponeko V, Abdelkarim H, Boyd MR, Gorman G, Manne U, Bae S, El-Rayes BF, Piazza GA. Foote JB, et al. Cancer Res. 2025 Mar 3;85(5):956-972. doi: 10.1158/0008-5472.CAN-24-0323. Cancer Res. 2025. PMID: 39700396 Free PMC article.
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
Bandi DSR, Nagaraju GP, Sarvesh S, Carstens JL, Foote JB, Graff EC, Fang YD, Keeton AB, Chen X, Valiyaveettil J, Berry KL, Bae S, Akce M, Gorman G, Yoon KJ, Manne U, Boyd MR, Buchsbaum DJ, Azmi AS, Maxuitenko YY, Piazza GA, El-Rayes BF. Bandi DSR, et al. Mol Cancer. 2025 Mar 13;24(1):76. doi: 10.1186/s12943-025-02288-9. Mol Cancer. 2025. PMID: 40082968 Free PMC article.
404 results